Vanda Pharmaceuticals’ (VNDA) Buy Rating Reiterated at Oppenheimer
Vanda Pharmaceuticals (NASDAQ:VNDA)‘s stock had its “buy” rating reissued by investment analysts at Oppenheimer in a research note issued to investors on Thursday.
Several other brokerages also recently commented on VNDA. BidaskClub downgraded Vanda Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Saturday, March 17th. Jefferies Group reaffirmed a “buy” rating and issued a $20.00 price objective on shares of Vanda Pharmaceuticals in a research report on Tuesday, February 13th. Seaport Global Securities reaffirmed a “buy” rating and issued a $21.00 price objective on shares of Vanda Pharmaceuticals in a research report on Wednesday, February 28th. Finally, ValuEngine raised Vanda Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Wednesday, December 20th. Two research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. The stock has an average rating of “Buy” and a consensus price target of $21.57.
Vanda Pharmaceuticals stock traded up $0.07 during midday trading on Thursday, hitting $17.02. The stock had a trading volume of 81,846 shares, compared to its average volume of 715,245. The company has a market cap of $852.40, a P/E ratio of -50.06 and a beta of 1.02. Vanda Pharmaceuticals has a 52-week low of $11.90 and a 52-week high of $20.40.
In other Vanda Pharmaceuticals news, CFO James Patrick Kelly sold 8,532 shares of the company’s stock in a transaction on Thursday, March 1st. The stock was sold at an average price of $18.72, for a total value of $159,719.04. Following the completion of the sale, the chief financial officer now directly owns 208,066 shares in the company, valued at approximately $3,894,995.52. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, SVP Gunther Birznieks sold 8,568 shares of the company’s stock in a transaction on Tuesday, January 2nd. The stock was sold at an average price of $15.26, for a total value of $130,747.68. Following the completion of the sale, the senior vice president now owns 118,366 shares of the company’s stock, valued at $1,806,265.16. The disclosure for this sale can be found here. Insiders sold a total of 287,506 shares of company stock valued at $4,665,795 over the last quarter. Company insiders own 7.60% of the company’s stock.
Several hedge funds have recently modified their holdings of VNDA. MetLife Investment Advisors LLC purchased a new stake in shares of Vanda Pharmaceuticals during the 4th quarter worth $308,000. Metropolitan Life Insurance Co. NY acquired a new stake in Vanda Pharmaceuticals during the fourth quarter worth about $221,000. Macquarie Group Ltd. grew its holdings in Vanda Pharmaceuticals by 20.0% during the fourth quarter. Macquarie Group Ltd. now owns 2,268,691 shares of the biopharmaceutical company’s stock worth $34,484,000 after acquiring an additional 378,606 shares during the period. TIAA CREF Investment Management LLC grew its holdings in Vanda Pharmaceuticals by 5.1% during the fourth quarter. TIAA CREF Investment Management LLC now owns 446,482 shares of the biopharmaceutical company’s stock worth $6,787,000 after acquiring an additional 21,595 shares during the period. Finally, Teachers Advisors LLC grew its holdings in Vanda Pharmaceuticals by 0.8% during the fourth quarter. Teachers Advisors LLC now owns 702,028 shares of the biopharmaceutical company’s stock worth $10,671,000 after acquiring an additional 5,690 shares during the period. Institutional investors and hedge funds own 89.96% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: This report was first published by Watch List News and is the property of of Watch List News. If you are accessing this report on another site, it was illegally copied and reposted in violation of United States & international copyright & trademark legislation. The correct version of this report can be read at https://www.watchlistnews.com/vanda-pharmaceuticals-vnda-buy-rating-reiterated-at-oppenheimer/1956260.html.
Vanda Pharmaceuticals Company Profile
Vanda Pharmaceuticals Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies to address unmet medical needs. Its product portfolio includes HETLIOZ (tasimelteon), Fanapt (iloperidone), Tradipitant (VLY-686), Trichostatin A and AQW051. It offers HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24).
Receive News & Ratings for Vanda Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vanda Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.